Fri, Aug 29, 2014, 2:39 PM EDT - U.S. Markets close in 1 hr 21 mins

Recent

% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • mbbf49a mbbf49a May 4, 2013 4:03 PM Flag

    Dr. Scher...wilderguide... a few questions

    I found a lot of interesting info on him and by him at the Practice Update website. Can you help me with information regarding the presentation he is making at ASCO on CTC? Do you have a title? Any idea of what he is actually going to say? Has he studied Cabo directly in relation to CTC and would he be likely to propose that Cabo will extend OS? If so that would obviously be a game changer for the stock and presumably for advanced prostate cancer patients as well. Thanks for your help in advance. I owe you a beer or a toddy...your choice.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • $$$$
      Look here: Scher co-presented the Cabo mCRPC P2 RDT results. This presentation was represented by some of the foremost oncologic journeymen in modern PC therapeutics, including Dr Scher.

      Cabozantinib (XL184) in Chemotherapy-Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): Results from a Phase 2 Non-Randomized Expansion Cohort (Abstract #4513)

      M.R. Smith, C. Sweeney, D.E. Rathkopf, H.I. Scher, C. Logothetis, D.J. George, C.S. Higano, E.Y. Yu, A.L. Harzstark, E.J. Small, A.O. Sartor, M.S. Gordon, N.J. Vogelzang, D.C. Smith, M. Hussain, J.S. de Bono, N.B. Haas, C. Scheffold, Y. Lee, P.G. Corn

      If I had to pick from this list wrt Who's Who in PC treatment, there'd be some difficult choices in making a decision as to the top 3...all are extensively published and highly regarded in their field. My faves to present are Matt Smith, H. Scher, Chris Logothetis, Dan George, Tia Higano, Oliver Sartor, Nick Vogelzang, Maha Hussein, Johann Debono, & Paul Corn...and that's practically the entire list. These are all heavy hitters in PC research. You really can't go wrong w/ any of them.
      In addition, if you Google "cabozantinib dinner date"...you'll find that some of these oncodocs have assisted in recruiting the Comet 1 & 2 trials in Europe.
      GL

      • 2 Replies to wilderguide
      • Thanks very much for this. I have my #$%$ hanging out in the breeze and I appreciate the help. Not only do I own a boatload of EXEL, now, as a result of my blabbing about it, so too do my father in law, friends, acquaintances, passing strangers, eavesdroppers in restaurants, and for all I know the Federal Reserve itself. If this goes wrong it could bring down our entire economy and end western civilization as we know it .

      • $$$$
        "Has he studied Cabo directly in relation to CTC...??
        This is of course only my conjecture, but given Doc Scher's research pursuit wrt CTC enumeration, his past experience with the Cabo RDT, and Cabo's known CTC therapeutic response... I would be compelled to answer "Undoubtedly..."

        " ...and would he be likely to propose that Cabo will extend OS? "
        Again, my opinion. But that opinion is also "yes"...

        If so that would obviously be a game changer for the stock...
        I agree.
        GL

 
EXEL
4.10+0.06(+1.49%)2:38 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.